---
title: "Daraxonrasib shows activity in RAS‑mutant NSCLC after FDA approval in pancreatic cancer"
id: "medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer/"
published_at: "2026-09-11T15:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Daraxonrasib shows activity in RAS‑mutant NSCLC after FDA approval in pancreatic cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/pancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer/)
- **Published At:** 2026-09-11T15:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- An oral drug already approved by the FDA for metastatic pancreatic cancer, **daraxonrasib (Rasonque)**, has shown activity in people with previously treated, advanced non–small cell lung cancer (NSCLC) that harbors **RAS** mutations, according to a phase 1–2 trial reported in the New England Journal of Medicine. - The trial enrolled adults with RAS‑mutant NSCLC who had disease progression or unacceptable toxicity on prior therapies. Investigators tested daily doses from 10 mg to 400 mg but focused the main analysis on 136 participants who received 300 mg or less because of dose modifications at the highest dose. - Overall response rates exceeded 30% across dose groups: 31% for ≤120 mg, 34% for 160–220 mg, and 37% for 300 mg. In an exploratory subgroup of 38 participants receiving 160–220 mg, the response rate was 42% and disease control was 89% for at least four weeks. - For responders in the exploratory group, median duration of response was 11.5 months, median progression‑free survival was 8.3 months, and median overall survival was 16 months. The study was not randomized and did not compare daraxonrasib with standard therapies, so survival benefit cannot be confirmed. - Nearly all participants experienced at least one adverse event; more than half had grade ≥3 events (pneumonia, diarrhea, rash, anemia). Investigators attributed grade ≥3 adverse events to daraxonrasib in 30% of participants. Common toxicities included rash, mucositis, diarrhea, nausea, and vomiting, often managed with dose adjustments and supportive care. - **Daraxonrasib** is a RAS(ON) multiselective inhibitor that targets active RAS across multiple proteins and mutations, differing from drugs that target a single inactive RAS variant such as KRAS G12C. - Experts not involved in the trial described the results as encouraging and noted the importance of head‑to‑head comparison with current standard treatments in a planned randomized phase 3 trial to establish clinical benefit. - The findings are preliminary and derived from a small, early‑phase study; further randomized research is required to determine whether daraxonrasib improves outcomes compared with existing options for RAS‑mutant NSCLC.
## Clinical Analysis & Structured Key Points
[Medical News Today](https://www.medicalnewstoday.com/) * Health Conditions Health Conditions * [Alzheimer's & Dementia](https://www.medicalnewstoday.com/alzheimers-and-dementia) * [Anxiety](https://www.medicalnewstoday.com/anxiety) * [Asthma & Allergies](https://www.medicalnewstoday.com/asthma-and-allergies) * [Atopic Dermatitis](https://www.medicalnewstoday.com/program/investigating-atopic-dermatitis) * [Breast Cancer](https://www.medicalnewstoday.com/breast-cancer) * [Cancer](https://www.medicalnewstoday.com/cancer) * [Cardiovascular Health](https://www.medicalnewstoday.com/cardiovascular-health) * [COVID-19](https://www.medicalnewstoday.com/coronavirus?correlationId=2b137d5a-dcfb-464e-9ea6-72c5a54b4e92) * [Diabetes](https://www.medicalnewstoday.com/diabetes) * [Endometriosis](https://www.medicalnewstoday.com/endometriosis) * [Environment & Sustainability](https://www.medicalnewstoday.com/environment-and-sustainability) * [Exercise & Fitness](https://www.medicalnewstoday.com/exercise-and-fitness) * [Eye Health](https://www.medicalnewstoday.com/eye-health) * [Headache & Migraine](https://www.medicalnewstoday.com/headache-and-migraine) * [Health Equity](https://www.medicalnewstoday.com/health-equity) * [HIV & AIDS](https://www.medicalnewstoday.com/hiv-and-aids) * [Human Biology](https://www.medicalnewstoday.com/human-biology) * [Leukemia](https://www.medicalnewstoday.com/leukemia) * [LGBTQIA+](https://www.medicalnewstoday.com/LGBTQIA) * [Men's Health](https://www.medicalnewstoday.com/mens-health) * [Mental Health](https://www.medicalnewstoday.com/mental-health) * [Multiple Sclerosis (MS)](https://www.medicalnewstoday.com/multiple-sclerosis) * [Nutrition](https://www.medicalnewstoday.com/nutrition) * [Parkinson's Disease](https://www.medicalnewstoday.com/parkinsons-disease) * [Psoriasis](https://www.medicalnewstoday.com/psoriasis) * [Sexual Health](https://www.medicalnewstoday.com/sexual-health) * [Ulcerative Colitis](https://www.medicalnewstoday.com/program/investigating-ulcerative-colitis) * [Women's Health](https://www.medicalnewstoday.com/womens-health) * Health Products Health Products [All](https://www.medicalnewstoday.com/products-and-reviews) * [Nutrition & Fitness](https://www.medicalnewstoday.com/products-and-reviews/nutrition-and-fitness-products) * [Vitamins & Supplements](https://www.medicalnewstoday.com/products-and-reviews/vitamin-and-supplement-products) * [CBD](https://www.medicalnewstoday.com/products-and-reviews/cbd-products) * [Sleep](https://www.medicalnewstoday.com/products-and-reviews/sleep-products) * [Mental Health](https://www.medicalnewstoday.com/products-and-reviews/mental-health-services-and-products) * [At-Home Testing](https://www.medicalnewstoday.com/products-and-reviews/at-home-testing-products) * [Men’s Health](https://www.medicalnewstoday.com/products-and-reviews/mens-health-products) * [Women’s Health](https://www.medicalnewstoday.com/products-and-reviews/womens-health-products) * Discover News * [Latest News](https://www.medicalnewstoday.com/news) * [Medicare 2026 Costs](https://www.medicalnewstoday.com/articles/medicare-costs-3-key-changes-in-2026) Original Series * [Medical Myths](https://www.medicalnewstoday.com/content-series/medical-myths) * [Honest Nutrition](https://www.medicalnewstoday.com/content-series/honest-nutrition) * [Through My Eyes](https://www.medicalnewstoday.com/content-series/through-my-eyes) * [New Normal Health](https://www.medicalnewstoday.com/content-series/new-normal-health) Podcasts [All](https://www.medicalnewstoday.com/articles/in-conversation-podcast) * [ADHD in women: Breaking the stereotypes](https://www.medicalnewstoday.com/articles/adhd-women-breaking-stereotypes-masking-attention-disorder) * [Is sleep the missing piece in mental health?](https://www.medicalnewstoday.com/articles/is-sleep-the-missing-piece-in-mental-health) * [Artificial sweeteners and brain aging: What we know so far](https://www.medicalnewstoday.com/articles/artificial-sweeteners-and-brain-aging-what-we-know-so-far) * [Does the Mediterranean diet hold the key to longevity?](https://www.medicalnewstoday.com/articles/does-the-mediterranean-diet-hold-the-key-to-longevity) * [AMA: Registered dietitian answers 5 key questions about fiber and weight loss](https://www.medicalnewstoday.com/articles/can-fiber-help-lose-weight-dietitian-answers-5-key-questions) * [Health misinformation and disinformation: How to avoid it](https://www.medicalnewstoday.com/articles/health-misinformation-and-disinformation-how-to-avoid-it) * Tools General Health * [Drugs A-Z](https://www.medicalnewstoday.com/drugs) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Newsletter](https://www.medicalnewstoday.com/newsletter) * [Medicare Plans by State](https://www.medicalnewstoday.com/about/health-medicare-state-coverage) Health Tools * [Find a Doctor](https://connect.medicalnewstoday.com/) * [BMI Calculators and Charts](https://www.medicalnewstoday.com/articles/323586) * [Blood Pressure Chart: Ranges and Guide](https://www.medicalnewstoday.com/articles/327077) * [Breast Cancer: Self-Examination Guide](https://www.medicalnewstoday.com/articles/316898) * [Sleep Calculator](https://www.medicalnewstoday.com/articles/sleep-calculator) Quizzes * [RA Myths vs Facts](https://www.medicalnewstoday.com/articles/science-fact-or-fiction-separating-ra-myths-from-facts#1) * [Type 2 Diabetes: Managing Blood Sugar](https://www.medicalnewstoday.com/articles/managing-blood-sugar-type-2-diabetes-quiz#1) * [Ankylosing Spondylitis Pain: Fact or Fiction](https://www.medicalnewstoday.com/articles/complementary-therapies-for-as-quiz#1) * Connect About Medical News Today * [Who We Are](https://www.medicalnewstoday.com/about) * [Our Editorial Process](https://www.medicalnewstoday.com/articles/process) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Conscious Language](https://www.medicalnewstoday.com/about/conscious-language) Find Community * [Bezzy Breast Cancer](https://www.bezzybc.com/lp/2/?verzenio&utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy MS](https://www.bezzyms.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Migraine](https://www.bezzymigraine.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Psoriasis](https://www.bezzypsoriasis.com/?utm_source=mnt&utm_medium=nav-bar-connect) Follow Us [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.instagram.com/medicalnewstoday/)[](https://www.linkedin.com/company/mednewstoday/?originalSubdomain=ec)[](https://flipboard.com/@MedNewsToday) Subscribe # Pancreatic cancer drug may also help fight treatment-resistant lung cancer ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/10/Erika-Watts-Bio-500x500-1.png?w=105&h=105) Written by Erika Watts on September 11, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. ![Radiology Doctor Wearing Lab Coat And Checking X-ray Image Of Chest](https://media.post.rvohealth.io/wp-content/uploads/sites/3/2026/09/getty_1253553934_header_1296x728-1024x575.jpg)[Share on Pinterest](https://www.pinterest.com/pin/create/button/?url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fpancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer&media=https%3A%2F%2Fmedia.post.rvohealth.io%2Fwp-content%2Fuploads%2Fsites%2F3%2F2026%2F09%2Fgetty_1253553934_header_1296x728-1024x575.jpg&description=Lung%20cancer%3A%20Drug%20approved%20by%20FDA%20for%20pancreatic%20cancer%20may%20help "Share on Pinterest")A drug approved by FDA for pancreatic cancer may help treat lung cancer, too. selimaksan/ Getty Images * **An experimental treatment may offer a new option for people with advanced lung cancer linked to RAS mutations.** * **The Food and Drug Administration (FDA) recently approved daraxonrasib (Rasonque) for certain people with metastatic pancreatic cancer, but researchers are also studying it for lung cancer.** * **In an early-stage trial, tumors shrank in more than 30% of participants who received the drug.** * **In a smaller subgroup, tumors shrank in 42% of participants, although researchers need a controlled trial to confirm the drug’s benefits.** Non-small cell lung cancer (NSCLC) is the [most common](https://pmc.ncbi.nlm.nih.gov/articles/PMC10001046/) type of [lung cancer](https://www.medicalnewstoday.com/articles/323701), and about 30% of people with this form of cancer have _RAS_ mutations. In a phase 1-2 clinical trial, researchers found that [daraxonrasibTrusted Source](https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer), an oral drug designed to block active RAS proteins that help cancer cells grow, could help people with NSCLC. While the results are promising, the study was small and did not compare daraxonrasib directly with another treatment. The study is published in the [New England Journal of Medicine](https://www.nejm.org/doi/10.1056/NEJMoa2504059). ## Daraxonrasib helped shrink lung cancer tumors NSCLC makes up around 85% of [lung cancer casesTrusted Source](https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html). According to the National Cancer Institute’s [SEER dataTrusted Source](https://seer.cancer.gov/statfacts/html/lungb.html), doctors diagnose 51% of lung and bronchus cancers after the cancer has spread to distant parts of the body. The _[RAS](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866659/)_[ gene family](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866659/) includes the _KRAS_ , _NRAS_ , and _HRAS_ genes, which encode proteins that help control when cells grow and stop growing. When _RAS_ mutations [occur](https://pmc.ncbi.nlm.nih.gov/articles/PMC9656434/), this leaves the process switched “on,” allowing cancer cells to continue growing and spreading. Researchers have historically found RAS proteins [difficult to target](https://pmc.ncbi.nlm.nih.gov/articles/PMC3128641/) with drugs. [TreatmentsTrusted Source](https://www.cell.com/cancer-cell/fulltext/S1535-6108\(26\)00010-3) now exist for cancers with specific mutations, such as _KRAS G12C_ , but most _RAS_ mutations still lack an approved [targeted therapy](https://www.medicalnewstoday.com/articles/targeted-therapy-lung-cancer-works). [Daraxonrasib](https://www.asco.org/practice-patients/patient-resources/research-summaries/RASolute-302-pancreatic-cancer) is a targeted drug known as a RAS(ON) multiselective inhibitor. Unlike treatments that target a single inactive form of RAS, it [blocksTrusted Source](https://pubmed.ncbi.nlm.nih.gov/42090791/) active RAS across multiple proteins and mutations. For the phase 1-2 study, the research team recruited adults with previously treated, advanced _RAS_ -mutant [NSCLC](https://www.medicalnewstoday.com/articles/non-small-cell-lung-cancer). The participants had either experienced cancer progression or had “unacceptable side effects” during their prior treatments. The researchers tested daily doses of daraxonrasib ranging from 10 to 400 milligrams (mg). However, frequent dose modifications at 400 mg led them to limit the main analysis to 136 participants who received 300 mg or less. The researchers primarily evaluated the drug’s safety. They also examined tumor response and survival outcomes. More than 30% of participants responded to treatment. **Tumors shrank in 31% of participants taking 120 mg or less, 34% taking 160-220 mg, and 37% taking 300 mg.** ## Daraxonrasib produced similar results across different doses In an exploratory analysis, the researchers examined 38 participants who received 160-220 mg of daraxonrasib. The people in this group had previously received [chemotherapy](https://www.medicalnewstoday.com/articles/158401) and [immunotherapy](https://www.medicalnewstoday.com/articles/immunotherapy) but had not received docetaxel, the chemotherapy drug researchers plan to compare with daraxonrasib in the phase 3 trial. In this smaller group, tumors shrank in 42% of participants. Daraxonrasib controlled the cancer in 89% of this group, meaning their tumors either shrank or did not grow for at least 4 weeks. **For the participants whose tumors responded, the response lasted a median of 11.5 months. They lived for a median of 8.3 months without their cancer worsening, and median overall survival was 16 months.** However, the study did not compare daraxonrasib directly with another treatment, so researchers cannot conclude that the drug extends survival at this point. They plan to investigate it further in a randomized phase 3 trial. Nearly all participants experienced at least one [adverse event](https://www.medicalnewstoday.com/articles/196135) during the study, although researchers did not consider every event related to daraxonrasib. More than half of participants experienced grade 3 or higher adverse events, including [pneumonia](https://www.medicalnewstoday.com/articles/151632), diarrhea, rash, and anemia. Researchers attributed adverse events of this severity to daraxonrasib in 30% of participants. Some common side effects the group had included rash, mouth sores, diarrhea, nausea, and vomiting. Their doctors managed many of the side effects by adjusting their medication dose and providing other care. ![JOIN NOW](https://i0.wp.com/healthline-activation-prod.healthline.com/driver-images/generict2drecipesimage.jpg) HEALTHLINE NEWSLETTER Get our free cancer-friendly recipes We rounded up a few nutritious recipes to help nourish your body during cancer treatment. Join our cancer care newsletter for your free recipes and expert guidance once a week. Enter your email JOIN NOW Your [privacy](https://www.medicalnewstoday.com/about/privacy-notice) is important to us ## Why targeting several _RAS_ mutations could matter [Nilesh Vora](https://www.memorialcare.org/providers/nilesh-l-vora), MD, a board-certified hematologist and medical oncologist and medical director of the MemorialCare Todd Cancer Institute at Long Beach Medical Center in California, spoke with _Medical News Today_ about the findings. **“I find these results encouraging because they could potentially give us another tool to improve both the quality and length of life for patients with cancer,” said Vora, who was not involved in the study.** However, he stressed the need to compare the drug directly with existing treatments. “I would like to see daraxonrasib directly compared with the current standard of care in a phase 3 clinical trial,” Vora added. “That kind of head-to-head comparison will be important in determining whether this approach provides a meaningful benefit over the treatments we currently use.” [Sonia Thomas](https://www.pcom.edu/academics/faculty/soniapa.html), PharmD, a clinical oncology pharmacist and professor and vice chair of pharmacy practice at the Philadelphia College of Osteopathic Medicine, also told _MNT_ that she found the results encouraging. Thomas, who was likewise not involved in this study, explained that most existing KRAS drugs target a specific mutation, while daraxonrasib targets the active form of several RAS proteins. “Rather than having one key that fits one specific KRAS mutation, daraxonrasib may be able to interfere with several different forms of RAS-driven cancer,” said Thomas. Thomas said this approach could make targeted therapy available to people whose RAS mutations currently have few or no targeted treatment options. However, she cautioned that promising early findings do not necessarily lead to a new standard treatment. * [Lung Cancer](https://www.medicalnewstoday.com/categories/lung-cancer) * [Pancreatic Cancer](https://www.medicalnewstoday.com/categories/pancreatic-cancer) * [Cancer / Oncology](https://www.medicalnewstoday.com/categories/cancer-oncology) * [Drugs](https://www.medicalnewstoday.com/categories/drugs) ### How we reviewed this article: History Share this article [](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fpancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer%3Futm_medium%3Dsocial%26utm_source%3Dfacebook%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on Facebook") [](https://twitter.com/intent/tweet?via=mnt&text=Lung%20cancer%3A%20Drug%20approved%20by%20FDA%20for%20pancreatic%20cancer%20may%20help&url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fpancreatic-cancer-drug-may-also-help-fight-treatment-resistant-lung-cancer%3Futm_medium%3Dsocial%26utm_source%3Dx%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on X") ![](https://i0.wp.com/post.medicalnewstoday.com/wp-content/uploads/sites/3/2021/10/Erika-Watts-Bio-500x500-1.png?w=105&h=105) Written by Erika Watts on September 11, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. ## Was this article helpful? YesNo ### Related Coverage * [](https://www.medicalnewstoday.com/articles/experimental-kras-vaccine-may-help-prevent-pancreatic-cancer?utm_source=ReadNext) [Experimental KRAS vaccine may help prevent pancreatic cancer](https://www.medicalnewstoday.com/articles/experimental-kras-vaccine-may-help-prevent-pancreatic-cancer?utm_source=ReadNext) [An experimental vaccine that targeted the mutated KRAS protein linked to pancreatic cancer was safe and produced a good immune response in a recent…](https://www.medicalnewstoday.com/articles/experimental-kras-vaccine-may-help-prevent-pancreatic-cancer?utm_source=ReadNext) [READ MORE](https://www.medicalnewstoday.com/articles/experimental-kras-vaccine-may-help-prevent-pancreatic-cancer?utm_source=ReadNext) * [](https://www.medicalnewstoday.com/articles/drugs-onivyde-cost?utm_source=ReadNext) [Onivyde (irinotecan liposome) and cost](https://www.medicalnewstoday.com/articles/drugs-onivyde-cost?utm_source=ReadNext) [Onivyde is a prescription drug used to treat metastatic pancreatic cancer. Learn how to lower long-term costs and more.](https://www.medicalnewstoday.com/articles/drugs-onivyde-cost?utm_source=ReadNext) [READ MORE](https://www.medicalnewstoday.com/articles/drugs-onivyde-cost?utm_source=ReadNext) * [](https://www.medicalnewstoday.com/articles/intraductal-papillary-mucinous-neoplasm?utm_source=ReadNext) [Intraductal papillary mucinous neoplasm](https://www.medicalnewstoday.com/articles/intraductal-papillary-mucinous-neoplasm?utm_source=ReadNext) [Intraductal papillary mucinous neoplasm (IPMN) is a noncancerous cyst in the ducts of the pancreas. Read more.](https://www.medicalnewstoday.com/articles/intraductal-papillary-mucinous-neoplasm?utm_source=ReadNext) [READ MORE](https://www.medicalnewstoday.com/articles/intraductal-papillary-mucinous-neoplasm?utm_source=ReadNext) * [](https://www.medicalnewstoday.com/articles/tumor-marker-for-pancreatic-cancer-pancreas?utm_source=ReadNext) [What to know about tumor markers for pancreatic cancer](https://www.medicalnewstoday.com/articles/tumor-marker-for-pancreatic-cancer-pancreas?utm_source=ReadNext) [Tumor markers can help healthcare professionals diagnose pancreatic cancer. Learn more here. ](https://www.medicalnewstoday.com/articles/tumor-marker-for-pancreatic-cancer-pancreas?utm_source=ReadNext) [READ MORE](https://www.medicalnewstoday.com/articles/tumor-marker-for-pancreatic-cancer-pancreas?utm_source=ReadNext) * [](https://www.medicalnewstoday.com/articles/ascites-pancreatic-cancer?utm_source=ReadNext) [What to know about ascites and pancreatic cancer](https://www.medicalnewstoday.com/articles/ascites-pancreatic-cancer?utm_source=ReadNext) [Pancreatic cancer can cause ascites, or fluid buildup in the abdomen. Learn about why this can happen, the symptoms, treatments, and more.](https://www.medicalnewstoday.com/articles/ascites-pancrea
## Related Clinical Research

- [Carbon monoxide exposure may explain lower Parkinson's risk linked to smoking](https://medichelpline.com/clinical-feed/medical-news-today-0-why-smokers-may-have-a-lower-parkinson-s-risk-it-s-not-the-nicotine.md)
- [Replacing animal fats with plant fats linked to lower mortality after nonmetastatic prostate cancer](https://medichelpline.com/clinical-feed/medical-news-today-0-swapping-animal-fats-with-plant-fats-may-lower-risk-of-death-after-prostate.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [GSK Highlights Lung Cancer Data From Two Drugs — STAT+ Briefing](https://medichelpline.com/clinical-feed/stat-news-0-stat-gsk-touts-lung-cancer-data-from-two-drugs.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.